ライフサイエンスコーパス: keratoses

1 f 11 patients [45.5%] diagnosed with actinic keratoses).

2 h approximately 30% having 5 or more actinic keratoses.

3 gines or seborrheic keratoses, and 3 actinic keratoses.

4 reduce the rate of new premalignant actinic keratoses.

5 s in human skin SCC and precancerous actinic keratoses.

6 heir premalignant precursor lesions, actinic keratoses.

7 is effective for field treatment of actinic keratoses.

8 n eradicate clinical and subclinical actinic keratoses.

9 melanocytic nevi, blue nevi, and seborrheic keratoses.

10 ell as dysplastic precursor lesions, actinic keratoses.

11 ormalities, pigment dyschromias, and actinic keratoses.

12 ple of 40 skin lesions (8 nevi, 8 seborrheic keratoses, 7 basal cell carcinomas, 7 melanomas, 4 heman

13 Actinic keratoses, a precancerous benign skin growth and precurs

14 es, such as actinic keratoses and seborrheic keratoses, achieving 92% sensitivity and specificity.

15 Precancerous actinic keratoses (AKs) (17) and SCCs (27) expressed two telomer

16 Actinic keratoses (AKs) are small scaly red areas of skin charac

17 effective in reducing the number of actinic keratoses (AKs) for up to 6 months, but no randomized tr

18 thyl 5-aminolevulinic acid (MAL) for actinic keratoses (AKs) is as effective as conventional photodyn

19 lly favorable treatment modality for actinic keratoses (AKs).

20 y (PDT) is used extensively to treat actinic keratoses(AKs).

21 At 3-monthly visits, new actinic keratoses and basal-cell carcinomas were identified and

22 ations are seen in later precancers (actinic keratoses and Bowen's disease).

23 oamputation, distinctive starfish-like acral keratoses and moderate degrees of deafness.

24 f promoting sunscreen use to prevent actinic keratoses and nonmelanoma skin cancer.

25 ancerous skin abnormalities, such as actinic keratoses and seborrheic keratoses, achieving 92% sensit

26 mutant p53 clusters associated with actinic keratoses and squamous cell carcinomas.

27 in cancer biopsies for the presence of solar keratoses and the extent of solar elastosis.

28 Treating actinic keratoses and the surrounding skin area (i.e., field the

29 D4+ T cell-mediated immunity against actinic keratoses and, potentially, cancers of the skin and othe

30 carcinomas, 7 solar lentigines or seborrheic keratoses, and 3 actinic keratoses.

31 five squamous cell carcinomas, five actinic keratoses, and one case of Bowen's disease) and HaCaT an

32 uding in normal skin, warts, dysplastic PUVA keratoses, and squamous cell carcinomas.

33 tinocyte carcinomas versus benign seborrheic keratoses; and malignant melanomas versus benign nevi.

34 Actinic keratoses arose in 9% of grafts treated with ultraviolet

35 arcinomas, squamous cell carcinomas, actinic keratoses, atypical nevi, melanocytic nevi, blue nevi, a

36 ed peeling skin, leukonychia, acral punctate keratoses, cheilitis, and knuckle pads, which we propose

37 in the 5 years prior to enrollment, actinic keratoses count at enrollment, a history of ever use of

38 ciformis keratosis and in some cases actinic keratoses demonstrated similar histology associated with

39 al-cell carcinomas and the number of actinic keratoses during the 12-month intervention period, the n

40 methods are viable ways to evaluate actinic keratoses, even when the investigators differ at differe

41 cancer, seven of 17 (41.2%) dysplastic PUVA keratoses, four of five (80%) skin warts, and four of 12

42 nce of untreated skin malignancy and actinic keratoses in high-risk kidney and liver transplant recip

43 of new nonmelanoma skin cancers and actinic keratoses in high-risk patients.

44 6.3% mean reduction in the number of actinic keratoses in participants (P < 0.0001).

45 = 11) than in cSCC in situ (n = 69), actinic keratoses (n = 63), and normal skin (n = 5).

46 Actinic keratoses on the face and ears were counted by study der

47 , we randomly assigned patients with actinic keratoses on the face or scalp or on the trunk or extrem

48 tive cells, unlike the situation for actinic keratoses or basal cell carcinomas.

49 entage of reduction in the number of actinic keratoses (primary outcome), local skin reactions, and i

50 for 2 or 3 consecutive days to treat actinic keratoses produced clinically relevant sustained clearan

51 (ROC = 0.823); and melanomas from seborrheic keratoses (ROC = 0.898).

52 plaques, and large tumors resembling actinic keratoses, SCC in situ, and SCCs, respectively.

53 those for presumptive skin cancer or actinic keratoses, skin biopsies, or PCP diagnostic accuracy wit

54 Seborrheic keratoses (SKs) are common benign skin tumors that share

55 Seborrheic keratoses (SKs) are common, benign epithelial tumors of

56 pproved for the topical treatment of actinic keratoses, superficial basal cell carcinoma, and genital

57 target genes were activated in some actinic keratoses, the major precancerous lesion in human skin.

58 sing option to evaluate emerging new actinic keratoses therapies.

59 Dermatologists treat actinic keratoses to prevent non-melanoma skin cancer.

60 The number of actinic keratoses was 11% lower in the nicotinamide group than i

61 The annualised rate of new actinic keratoses was 8.2 among the patients assigned T4N5 lipos

62 ve measures, other skin cancers, and actinic keratoses were not.

63 tly younger, had more nevi but fewer actinic keratoses, were more likely to report a family history o

64 with premalignant lesions resembling actinic keratoses, whereas those in the heterozygous and wild-ty